BC
GILD icon

Brookfield Corp’s Gilead Sciences GILD Stock Holding History

Brookfield Corp’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,637
Closed -$203K – 281
2023
Q2 		$203K Sell
2,637
-32,291
-92% -$2.58M ﹤0.01% 574
2023
Q1 		$2.9M Buy
34,928
+17,374
+99% +$1.44M 0.01% 375
2022
Q4 		$1.51M Sell
17,554
-282,594
-94% -$22.4M 0.01% 452
2022
Q3 		$18.5M Buy
300,148
+111,294
+59% +$7.02M 0.07% 100
2022
Q2 		$11.7M Buy
188,854
+72,022
+62% +$4.46M 0.05% 128
2022
Q1 		$6.95M Buy
+116,832
New +$7.47M 0.03% 204

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brookfield Corp's GILD Position: Q3 2023 in Review

Brookfield Corp sold out of Gilead Sciences (GILD) in Q3 2023, closing a stake of 2,637 shares — an estimated $203K sold.

Brookfield Corp first reported a position in GILD in Q1 2022 and held it in 6 quarters. The position peaked at $18.5M in Q3 2022. 1,683 funds tracked by Wall St. Rank hold GILD as of Q3 2023.

  • Brookfield Corp reported no remaining Gilead Sciences position as of Q3 2023 after selling out during the quarter.
  • Brookfield Corp sold 2,637 Gilead Sciences shares in Q3 2023, an estimated $203K.
  • Brookfield Corp first reported a position in Gilead Sciences in Q1 2022 and held it in 6 quarters.
  • Brookfield Corp's Gilead Sciences position peaked at $18.5M in Q3 2022.
  • 1,683 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2023.

Based on Brookfield Corp's 13F filing for Q3 2023, filed 14 Nov 2023.